<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2012-6074-282-12263</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Exploration of potentially antimycobacterial and antituberculosis natural products from Tanzanian plants</narrative>
   <narrative xml:lang="SV">Unders&#xF6;kning av potentiellt antimikrobiella och antituberkulotiska naturprodukter i Tanzaniska v&#xE4;xter</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="SV">Nya l&#xE4;kemedel mot tuberkulos fr&#xE5;n afrikanska naturprodukter Tuberkulos &#xE4;r en mycket utspridd infektionssjukdom. En tredjedel av jordens befolkning b&#xE4;r p&#xE5; bakterierna och ungef&#xE4;r tv&#xE5; miljoner m&#xE4;nniskor d&#xF6;r varje &#xE5;r som resultat av sjukdomen, de flesta i Asien och i Afrika. Tuberkulos drabbar oftast barn och &#xE4;ldre personer. &#xC4;ven om antalet infektioner har sjunkit de senaste decennierna i Europa och Nord-Amerika &#xE4;r denna trend p&#xE5; v&#xE4;g att v&#xE4;nda. Detta &#xE4;r framf&#xF6;rallt en konsekvens av uppkomsten och spridningen av bakteriestammar som &#xE4;r resistenta mot dagens l&#xE4;kemedel samt av en &#xF6;kad spridning av sjukdomen vid nedsatt funktion av immunsystemet, t.ex. som f&#xF6;ljd av HIV infektion som i sig sj&#xE4;lv &#xE4;r ett stort problem till exempel i Afrika. Spridningen av multiresistenta tuberkulosbakterier samt HIV har f&#xF6;rorsakat en allvarlig situation med h&#xF6;g risk f&#xF6;r en framtida global epidemi. I detta projekt kommer en tanzanisk och tv&#xE5; svenska forskargrupper att samarbeta med m&#xE5;let att hitta utg&#xE5;ngspunkter till nya tuberkulosl&#xE4;kemedel igenom att unders&#xF6;ka v&#xE4;xter som anv&#xE4;nds mot tuberkulos i Tanzania. V&#xE4;xterna kommer att samlas i Tanzania och studeras med kemiska och biologiska metoder i Sverige. Bioaktiva komponenter av v&#xE4;xternas extrakter kommer att isoleras och strukturbest&#xE4;mmas. Deras toxicitet och antituberkulotiska aktivitet kommer att best&#xE4;mmas och m&#xF6;jligheten av att anv&#xE4;nda flera substanser f&#xF6;r att uppn&#xE5; starkare effekt och mindre risk f&#xF6;r resistensutveckling kommer att unders&#xF6;kas. De mest lovande substanserna kommer att modifieras med kemiska metoder f&#xF6;r att uppn&#xE5; &#xE4;nnu starkare effekt och d&#xE4;rmed kunna anv&#xE4;ndas i modern l&#xE4;kemedelsutveckling. Samarbetet kommer att ge utbildning till den afrikanska samarbetspartnern i moderna instrumentella forskningsmetoder och f&#xF6;rv&#xE4;ntas att leverera viktiga kunskaper f&#xF6;r utvecklingen av morgondagens tuberkulosl&#xE4;kemedel.</narrative>
   <narrative xml:lang="EN">The proposed collaborative research is aimed at designing a combination treatment targeted against Mycobacterium tuberculosis infection using co-administration of natural products from Tanzanian medicinal plants or their synthetic analogues with currently ineffective anti-TB drugs. The targeted plant species will be those traditionally used in treatment of TB or related respiratory infections of which our recent work have indicated to exhibit antimicrobial activities yet have not been thoroughly investigated for their antimycobacterial activity and anti-TB drug enhancement ability. The project will involve plant extracts preparation, bioassay guided isolation of plant natural products for targeted bioactivities to be done at the University of Dar es Salaam (UDSM). Further purification and structural determination of the bioactive metabolites which shall require access to preparative High Performance Liquid Chromatography systems and spectroscopic facilities which are unavailable in Tanzania, will be conducted in collaboration with the University of Gothenburg (GU). Furthermore, syntheses of isolated bioactive molecules and their analogues to be done at GU and UDSM as well as molecular and biological assays to study their mode of actions (GU) shall serve a crucial step in adding value to the applications of the compounds towards discovery of novel anti-TB agents that could be used in TB combination therapy.</narrative>
  </description>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">G&#xF6;teborgs universitet</narrative>
  </participating-org>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2013-01-01" type="1"></activity-date>
  <activity-date iso-date="2013-01-01" type="2"></activity-date>
  <activity-date iso-date="2015-12-31" type="3"></activity-date>
  <activity-date iso-date="2015-12-31" type="4"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="TZ" percentage="100">
   <narrative xml:lang="EN">Tanzania, United Republic of</narrative>
  </recipient-country>
  <sector code="122" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Basic Health</narrative>
  </sector>
  <sector code="12263" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Tuberculosis control</narrative>
  </sector>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2013-01-01"></period-start>
   <period-end iso-date="2013-12-28"></period-end>
   <value currency="USD" value-date="2013-01-01">38383.5902474974</value>
  </budget>
  <budget>
   <period-start iso-date="2014-01-01"></period-start>
   <period-end iso-date="2014-12-28"></period-end>
   <value currency="USD" value-date="2014-01-01">36443.6799370253</value>
  </budget>
  <budget>
   <period-start iso-date="2015-01-01"></period-start>
   <period-end iso-date="2015-12-28"></period-end>
   <value currency="USD" value-date="2015-01-01">29658.453252346</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2012-11-22"></transaction-date>
   <value currency="USD" value-date="2012-11-22">110800.8686788104</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2014-01-28"></transaction-date>
   <value currency="USD" value-date="2014-01-28">36443.6799370253</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2015-01-28"></transaction-date>
   <value currency="USD" value-date="2015-01-28">29658.453252346</value>
  </transaction>
  <document-link format="APPLICATION/PDF" url="http://upload.openaid.se/document/ingen-myndighet-vald/generella-bidragsvillkor-2013.pdf">
   <title>
    <narrative xml:lang="SV">Generella bidragsvillkor 2013</narrative>
   </title>
   <category code="A04"></category>
  </document-link>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
